Sign in →

Test Code GM1 Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies

Performing Laboratory

ARUP

Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Reference Values

Components

Reference Interval

 

Asialo-GM1 Antibodies, IgG/IgM

29 IV or less

Negative

30-50 IV

Equivocal

51-100 IV

Positive

101 IV or greater

Strong Positive

 

GM1 Antibodies, IgG/IgM

29 IV or less

Negative

30-50 IV

Equivocal

51-100 IV

Positive

101 IV or greater

Strong Positive

 

GM2 Antibodies, IgG/IgM

29 IV or less

Negative

30-50 IV

Equivocal

51-100 IV

Positive

101 IV or greater

Strong Positive

 

GD1a Antibodies, IgG/IgM

29 IV or less

Negative

30-50 IV

Equivocal

51-100 IV

Positive

101 IV or greater

Strong Positive

 

GD1b Antibodies, IgG/IgM

29 IV or less

Negative

30-50 IV

Equivocal

51-100 IV

Positive

101 IV or greater

Strong Positive

 

GQ1b Antibodies, IgG/IgM

29 IV or less

Negative

30-50 IV

Equivocal

51-100 IV

Positive

101 IV or greater

Strong Positive

 

Test Classification and CPT Coding

83516 x 6

Specimen Required

Container/Tube:   Gold Top Tube

Specimen:  0.3 mL serum (0.1 mL min)

Transport Temperature:  Refrigerated

Stability: 14 Days Refrigerated

                1 Year Frozen

                 Unacceptable Room Temperature

Computer Interface Code

PDM # 5903910

Used For

Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1) and the neutral glycolipid, asialo-GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80% of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease